CRITICAL BLEEDING PROTOCOL

POWH/RHW

Principles of Critical Bleeding Management

- Early recognition of blood loss
- Maintenance of tissue perfusion and oxygenation by restoration of blood volume and haemoglobin
- Arrest bleeding with surgical or radiological intervention
- Judicious use of blood component therapy to correct coagulopathy

Criteria for identifying patients at risk massive haemorrhage

- Patients likely to need replacement entire blood volume in 24 hours
- Patients with at least 1 of severe thoracic, abdominal or pelvic injury
- Patients who are receiving or have received transfusion of 4 units of RBC in < 4 hrs
- In addition to haemodynamic instability and/or ongoing blood loss

Damage control during resuscitation

- Early consultant input to arrest haemorrhage and minimize microvascular bleeding & coagulopathy
- Surgical assessment/intervention; tourniquet; packing; compression
- Aggressive fluid resuscitation; active warming measures to try and avoid hypothermia & acidosis

Activation of Critical Bleeding Protocol (CBP)

- Senior medical officer notifies Blood bank directly (<u>ext 29145</u>), verifying whether it is ROTEM guided or Non- ROTEM
- Blood Bank may also identify a patient and ask the team if they want to activate the CBP
- If patient has no current group and hold, group O blood will be issued until pateitnis cross matched.
- Blood component therapy is then administered according to monitoring and and the CBP
- Component therapy may be altered by consultant in charge, particularly if initial values abnormal, clinical conditions (e.g. liver failure) suggest coagulopathic risk or patient received blood products prior to arriving POWH
- Decision to ceae CBP is that of senior medical officer in charge and must be communicated directly to Blood Bank

ROTEM Guided

- <u>An 'Authority to Issue Blood Products' (pink form)'</u> for all products requested must be sent with staff member collecting products
- PRBC requested based on estimated loss and HB from blood gas machine and formal FBC
- Refer to Cardiac/Vascular ROTEM algorithm OR
- Refer to General surgical/Obstetric Haemorrhage ROTEM Algorithm
- Ensure ROTEM trace is repeated 10 minutes after each intervention and results recored in notes
- Multiplate to be ordered and interpreted according to POWH Multiplate schedule

NON-ROTEM Guided

- An 'Authority to Issue Blood Products' (pink form)' for all products requested must be sent with staff member collecting products
- If bleeding continues, alternate Pack 1 and Pack 2
- PACK 1: 4 units PRBC; 4 units ELP; 3 units apheresis cryoprecipitate
- PACK 2: 4 units PRBC; 4 units ELP; 1 bag platelets

Additional suggested if:

- **Platelets** if count < 50 or < 100 with head injury
- **Cryoprecipitate** if fibrinogen < 1.5 g/dL
- ELP if PT, APTT prolonged & provided fibrinogen > 1
- **PRBC** if Hb < 80 g/L and ongoing blood loss
- Calcium chloride if ionised calcium < 1.1 mmol/L

Monitoring

• FBC, EUC, LFTs, ionised calcium, PT/APTT, Fibrinogen, BG, Group/crossmatch initially

- FBC, EUC, PT/APTT, fibrinogen, BG every 60 mins during resuscitation
- Ionised calcium should also be monitored

Tranexamic acid

- In trauma patients with significant haemorrhage consider Tranexamic acid - 1g IV loading dose over 10 mins; followed by 1g IV infusion over 8 hrs
- Also safe and effective in postpartum haemorrhage
- 500mg/5ml ampoules available in pharmacy and Afterhours Drug Room.

Recombinant Activated Factor (rFVIIa)

- No randomised trial has demonstrated survival advantage in lifethreatening bleeding
- Patient pH should be > 7.2 for procoagulant effect
- Every effort should be made to correct surgical bleeding
- Authorisation required by consultant Haematologist on-call
- Dose: 90 microg/kg rounded to nearest whole vial, given as IV bolus over 2 to 5 mins. A second dose may be required 2 to 4 hours later
- Kept in Blood Bank


BUSINESS RULE COVER SHEET



Prince of Wales/Sydney-Sydney Eye Hospitals and Health Services

Critical Bleeding Protocol

POWH CLIN072



Content Manager N°; T18/48875 Date: July 2020 Page 11 of 12 THIS DOCUMENT BECOMES UNCONTROLLED WHEN PRINTED OR DOWNLOADED UNLESS REGISTERED BY LOCAL DOCUMENT CONTROL PROCEDURES Template Content Manager N°: T19/28757

BUSINESS RULE COVER SHEET



Prince of Wales/Sydney-Sydney Eye Hospitals and Health Services

Critical Bleeding Protocol

POWH CLIN072

Appendix 2: Anticoagulation Table Anticoagulation Table ⁹


Anticoagulation monitoring and management in critical bleeding


Drug	Conventional coagulation tests Present Drug level		Reversible	Recommendations Contact haematology for further discussion				
Vitamin K antagonist (VKA) Warfarin	INR	INR	Yes	Prothrombinex-VF (mg/kg)* (+Vit K)				
				Initial INR	1.5-2.5	2.6-3.5	3.6-10.0	> 10.0
				Target INR 0.9-1.3	30	35	50	50
				Target INR: 1.4-2.0	15	25	30	40
Unfractionated heparin (UFH)	APTT	APTT	Yes	Protamine Maximum dose 50 mg 1 mg per 100 units of UFH intravenously, at a maximum rate of 5 mg/minute (Where the amount of UFH to be reversed = cumulative dose in preceding 3hrs)				
Low molecular weight heparin (LMWH) Enoxaparin	+∔ APTT	antiXa assay	Partial (60-75%)	Protamine Maximum dose 50 mg, maximum rate 5 mg/min < 8 hours post dose 1 mg per 100 units enoxaparin intravenously 8-12 hours post dose 0.5 mg per 100 units enoxaparin intravenously				
Dabigatran	APTT and TT	Dilute TT	Yes	 Idarucizumab (stored in Blood Bank) Refer to <u>SESLHDPR/571 Prescribing Protocol</u> 5 g intravenously (2x2.5g/50mL), by bolus injection or infusion 				
Rivaroxaban	PT*	Modified antiXa assay specific for Rivaroxaban	No	Consider pro-haemostatic agents: PCC, FEIBA				
Apixaban	+/- PT*	Modified antiXa assay specific for Apixaban	No	Consider pro-haemostatic agents: PCC, FEIBA				

^{Alf} Prothrombinex-VP is not available, use Extended Life Plasma (ELP) 10-15mL/kg for warfarin reversal. ^{Alf} Vitamin K should be co administered

"Vitamin K should be co-administered "PT sensitivity to DOACs will vary according to local laboratory reagents. In some laboratories the PT will be insensitive to DOACs.

Content Manager Nº: T18/48875 Date: July 2020 Page 12 of 12 THIS DOCUMENT BECOMES UNCONTROLLED WHEN PRINTED OR DOWNLOADED UNLESS REGISTERED BY LOCAL DOCUMENT CONTROL PROCEDURES Template Content Manager Nº: T19/28757





ROTEM between steps as indicated. This reduces unnecessary transfusion especially of ELP